Dayvigo FDA Approval History
Last updated by Judith Stewart, BPharm on Jan 27, 2021.
Dayvigo (lemborexant) is dual orexin receptor antagonist (DORA) for the treatment of insomnia.
Development Timeline for Dayvigo
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.